Gsk Plc · LSE:GSK
Gsk — Shareholder Meeting (May 2026)
5 slides from Gsk's shareholder meeting presentation, May 6, 2026
Slide 1: Annual General Meeting, 6 May 2026
6 May 2026 Luke Miels, Chief Executive Officer Annual General Meeting, 6 May 2026 gsk.com
Slide 2: Strong 2025 performance
Strong 2025 performance Specialty medicines growth drives sales and earnings Sales Core operating profit Core EPS £32.7bn £9.8bn 172.0p +7% +11% +12% Cash generated Dividend per share Responsible from operations Business rating £8.9bn 66p On track 2026 guidance: sales growth 3-5% and core operating
Slide 3: Key focus areas to drive value
Key focus areas to drive value Deliver Accelerate Simplify how growth R&D we work Maximise launch of next wave Focus on bringing late-stage Reduce complexity, focus resources products, ensure success in overall pipeline to patients faster on what matters most and operational execution and executing
Slide 4: Creating value for patients and shareholders
Creating value for patients and shareholders Pipeline delivery Accelerated Topline growth GSK R&D output including >£40bn sales by 2031 with product centricity, with continued focus on margin decisive progress and agility + continued BD improvement for 2031 and beyond Capital allocation for growth +
Slide 5: Summary
Summary • Strong 2025 performance • 2026 focus: grow, accelerate, simplify • Creating value for patients and shareholders 5